Free tool
Drugs in development
Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations
Drugs in development
3,685
Not FDA-approved
In Phase 3
1,424
Highest phase reached
Matching your filters
111
111 drugs in development
Names, sponsors and conditions come from the trial records. Click a drug for its trials.
- BMS-986368CC-97489Phase 22 trials
Bristol Myers Squibb · Agitation, Alzheimer Disease, Multiple Sclerosis Spasticity
- BPL-003Phase 22 trials
Beckley Psytech Limited · Treatment Resistant Depression
- DT-101Phase 22 trials
Draig Therapeutics Ltd · Major Depressive Disorder (MDD)
- IcalcaprantABBV-1354, CVL-354Phase 22 trials
AbbVie · Bipolar I Disorder, Bipolar II Disorder, Major Depressive Disorder
- ONO-2020Phase 22 trials
Ono Pharmaceutical Co., Ltd. · Agitation Associated With Alzheimer's Disease Dementia, Alzheimer Disease
- PEX010-Assisted TherapyPEX010Phase 22 trials
Filament Health Corp. · Stimulant Use Disorder, Opioid Use Disorder
- SPT-300LYT-300, GlyphAlloPhase 22 trials
Seaport Therapeutics · Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
- SunobinopV117957Phase 22 trials
Knoa Pharma LLC · Alcohol Use Disorder
- ZelquistinelGATE-251Phase 22 trials
Syndeio Biosciences, Inc · Major Depressive Disorder
- ACP-211Phase 21 trial
ACADIA Pharmaceuticals Inc. · Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
- ALKS 7290Phase 21 trial
Alkermes, Inc. · Attention Deficit Disorder With Hyperactivity (ADHD)
- ALTO-100Phase 21 trial
Alto Neuroscience · Bipolar Disorder I or II With a Major Depressive Episode
- ALTO-101Phase 21 trial
Alto Neuroscience · Schizophrenia, Cognitive Impairment
- ALTO-203Phase 21 trial
Alto Neuroscience · Major Depressive Disorder, Anhedonia
- ALTO-207Phase 21 trial
Alto Neuroscience · Treatment-resistant Depression (TRD)
- ALTO-300Phase 21 trial
Alto Neuroscience · Major Depressive Disorder
- BMS-986511EvifacotrepPhase 21 trial
Bristol Myers Squibb · Major Depressive Disorder
- BR5402APhase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- BR5402A-1Phase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- BR5402BPhase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- BR5402B-1Phase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- BR5402CPhase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- BR5402C-1Phase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- BR5402DPhase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- BR5402D-1Phase 21 trial
Boryung Pharmaceutical Co., Ltd · Schizophrenia
- CLE-100Phase 21 trial
Clexio Biosciences Ltd. · Adjunctive Treatment of Major Depressive Disorder (MDD)
- CMND-100MEAIPhase 21 trial
Clearmind Medicine Inc. · Alcohol Use Disorder
- CYB004Phase 21 trial
Cybin IRL Limited · Generalized Anxiety Disorder
- ELE-101Phase 21 trial
Eleusis Therapeutics · Healthy Volunteers, Major Depressive Disorder, Depression
- EMP-01Phase 21 trial
atai Therapeutics, Inc. · Social Anxiety Disorder
- ENA-001Phase 21 trial
Enalare Therapeutics Inc. · Respiratory Depression
- GM-1020Phase 21 trial
Gilgamesh Pharmaceuticals · Major Depressive Disorder
- GM-2505Phase 21 trial
AbbVie · Major Depressive Disorder
- GXV813Phase 21 trial
Novartis · Schizophrenia
- INDV-2000Phase 21 trial
Indivior Inc. · Opioid Use Disorder
- INDV-6001Phase 21 trial
Indivior Inc. · Moderate to Severe Opioid Use Disorder
- JNJ-89495120Phase 21 trial
Johnson & Johnson (Janssen) · Depressive Disorder, Major
- KYN-5356Phase 21 trial
Kynexis B.V. · Cognitive Impairment Associated With Schizophrenia (CIAS)
- LY03020Phase 21 trial
Luye Pharma Group Ltd. · Schizophrenia
- MT1988Phase 21 trial
Monument Therapeutics Limited · Clinical High Risk for Psychosis (CHR)
- NBI-1070770Phase 21 trial
Neurocrine Biosciences · Major Depressive Disorder
- NBI-1117570Phase 21 trial
Neurocrine Biosciences · Schizophrenia
- NH102Phase 21 trial
Jiangsu Nhwa Pharmaceutical Co., Ltd. · Major Depressive Disorder (MDD)
- NORA520Phase 21 trial
TWi Biotechnology, Inc. · Depression, Postpartum, Postpartum Depression, Post-partum Depression
- NS-136Phase 21 trial
NeuShen Therapeutics · Schizophrenia(Acute)
- NTX-1472Phase 21 trial
Newleos Therapeutics, Inc. · Social Anxiety Disorder (SAD)
- NV-5138SPN820Phase 21 trial
Navitor Pharmaceuticals, Inc. · Treatment Resistant Depression
- PDC-1421Phase 21 trial
BioLite, Inc. · Major Depressive Disorder
- PRT042Phase 21 trial
Sichuan Purity Pharmaceutical Technology Co., Ltd. · Major Depressive Disorder (MDD
- RE03Phase 21 trial
Reconnect Labs · Posttraumatic Stress Disorder (PTSD), Sleep Disturbances and Insomnia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.